Skip to content
‹ Back to IndustriesHealthcare

Development and Engineering Services That Push Innovations to Market: MarketScale Mornings

On this episode of MarketScale Mornings, hosts Taylor Bagley and Voice of B2B Daniel Litwin were joined by Paragon Innovations CEO and Founder Mike Wilkinson.   Founded in 1990 and counting companies like 3M, Hitachi, Medtronic, Motorola, and Siemens as clients, Paragon is one of the nation’s leading providers of turn-key product development and innovation…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
Development and Engineering Services That Push Innovations to Market: MarketScale Mornings

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

On this episode of MarketScale Mornings, hosts Taylor Bagley and Voice of B2B Daniel Litwin were joined by Paragon Innovations CEO and Founder Mike Wilkinson.

Founded in 1990 and counting companies like 3M, Hitachi, Medtronic, Motorola, and Siemens as clients, Paragon is one of the nation’s leading providers of turn-key product development and innovation and engineering services. With projects that span anywhere from Class I and Class II medical devices to cellular-based hunting cameras and even a new cellular-, GPS-, WiFi- and Bluetooth-enabled dog collar called Link that not only tracks man’s best friend, but features sensors that monitor a pet’s health and wellness and offers connectivity to the vet, Paragon has worked with a vast variety of industries—both established corporations and new startups—helping to push unique and highly creative innovations and ideas to market.

Wilkinson states that while some products may have similar systems that make it easier for them to engineer, Paragon’s ability to handle innovations that differ profoundly from industry to industry and product to product comes from truly listening to the customer and learning first-hand about their requirements.

“Our customers—they know their industry,” he explained. “What makes us unique from a lot of our competitors—both large companies and small—is that our engineers actually get into the field. They go out with the customer and learn about the needs and the real use cases so we’re not trapped by thinking what we think is the best idea is really the best idea.”

Wilkinson also described Paragon’s strategy in breaking down the customer’s specific needs in order to get products to market.

“Often they’ve got a big list of what they want to do,” he said. “We try to narrow it down to the MVP, or minimal viable product. What do we have to get done today to get a product to market? What we find is that if you’ll do that minimal viable product, the customers will tell you where you need to pivot down the road.”

Wilkinson also discussed tech breakthroughs like 3D printing and shrinking surface mount technologies that have enabled Paragon to more easily innovate new solutions, why people’s perceptions regarding the outsourcing of engineering and developing services during the 90s were a hindrance to their initial growth, how fluctuations in economies and catastrophic events affect their company’s business, the ongoing growth of the Texas technology culture, and so much more. But you can only hear it by tuning into the podcast.

Bringing thought leadership to your morning routine, MarketScale Mornings host industry experts so that you stay informed of the newest trends, events and beyond in B2B. And for the latest thought leadership, news and event coverage across B2B, be sure to check out our industry pages.

Fly to the future each week with Drones In America.

For the latest news, videos, and podcasts in the IoT Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

In a Diaceutics survey of 125 US pharma leaders, respondents rated the significance of converting diagnosis into treatment to future commercial success at an average of 7.5 out of 10. They rated their organizations' effectiveness at turning diagnostic insights into coordinated action at just 5.2 out of 10. Separate Diaceutics lung cancer research found the largest gap now occurs at the point of treatment decision.

  • 01Pharma leaders rated their confidence in identifying eligible patients at 6.6 out of 10, their visibility across the patient journey at 5.4 and their effectiveness at turning diagnostic insights into coordinated action at 5.2. The low last score could point to the treatment decision, where Diaceutics' lung cancer research found the largest gap now occurs.
  • 02In US advanced non-small cell lung cancer, Diaceutics found overall patient loss virtually unchanged at 65.1% in 2023 versus 64.4% in 2019, while patient loss at the point of treatment decision rose from 29.2% to 43.3%. For operators, a flat headline rate could hide one step getting worse.
  • 03Senior leaders from several top 20 pharma companies argue diagnostic planning belongs early in development and commercialization, rather than as a testing and adoption fix after launch.

Nov 22, 2026

Frequent use of clinical AI tools rose to 34% in Elsevier's 2026 clinician survey

Elsevier's Clinician of the Future 2026 survey found 49% of clinicians use AI at work. Purpose-built clinical AI is gaining fast. Its frequent use rose from 22% in 2025 to 34% this year, yet 41% of nurses say their views are rarely or never sufficiently considered in important organizational decisions.

  • 01A sharper vendor question: which evidence base grounds the tool's answers, and can a clinician see that source at the moment of use? Transparency and authoritative data top clinicians' own list of what builds trust.

Nov 22, 2026

Zoom's stake in Medaica aims to bring the physical exam into video visits

Zoom Ventures made an undisclosed strategic investment in Medaica, whose FDA-cleared M1 telehealth stethoscope supports real-time remote heart and lung auscultation. Zoom already integrates with EHRs including Epic, Oracle Cerner Millennium and Athenahealth, but an investment is not an integration and no combined product has been announced. Cardiology follow-ups and care facilities are highlighted as likely early use cases.

  • 01Video gave telehealth the patient's face; an FDA-cleared remote stethoscope adds the heartbeat, and Zoom now has a financial stake in that second layer.
  • 02Today's cleared capability is real-time heart and lung auscultation; the wider mix of third-party devices, AI analysis and decision support is still in development.
  • 03For health systems with elderly or rural cardiology panels, the sharper vendor question is how exam findings reach the EHR record of the visit.

Nov 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512